Their findings were published online Jan. 12 in Cancer Research.
Exploring yet another front in lung cancer science, a second study scheduled for release at the lung cancer conference suggests that lung cancer patients who are smokers seem better able than nonsmoking patients to tolerate higher -- and presumably more effective -- dosages of a standard chemotherapy treatment known as erlotinib.
The research team, from the Wake Forest University in Winston-Salem, N.C., found that while nonsmokers ultimately developed dangerously toxic side effects -- such as rashes, diarrhea and/or dehydration -- when placed on an average daily dose regimen of just 225 milligrams of erlotinib, smokers didn't develop similarly problematic reactions until the daily average dosage reached 300 milligrams.
For additional details on green tea and lung cancer prevention, visit the National Cancer Institute.
Copyright © 2011 HealthDay. All rights reserved.